2,4,4-trimethylpentene: a hazardous substance [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 7868 |
| CHEMBL ID | 3186786 |
| MeSH ID | M0101910 |
| Synonym |
|---|
| LS-13500 |
| 2,4,4-trimethylpent-1-ene |
| inchi=1/c8h16/c1-7(2)6-8(3,4)5/h1,6h2,2-5h |
| nsc 73942 |
| 2,4,4-trimethyl-1-pentene |
| hsdb 1442 |
| brn 1098309 |
| 2,2,4-trimethyl-4-pentene |
| einecs 203-486-4 |
| 1-methyl-1-neopentylethylene |
| ai3-30049 |
| 1-pentene,4,4-trimethyl- |
| 107-39-1 |
| 2,4-trimethyl-4-pentene |
| diisobutene |
| 2,4-trimethyl-1-pentene |
| diisobutylene |
| nsc-8701 |
| nsc8701 |
| 1-pentene, 2,4,4-trimethyl- |
| nsc-73942 |
| nsc73942 |
| 2,4,4-trimethyl-1-pentene, 96% |
| 2,4,4-trimethyl-1-pentene, 99% |
| NCGC00166004-01 |
| 2,4,4-trimethylpentene |
| 25167-70-8 |
| pentene, 2,4,4-trimethyl- |
| T0665 |
| NCGC00166004-02 |
| n69l73advf , |
| 4-01-00-00892 (beilstein handbook reference) |
| unii-n69l73advf |
| dtxcid806765 |
| cas-107-39-1 |
| tox21_200435 |
| NCGC00260103-01 |
| dsstox_rid_78589 |
| dsstox_gsid_27851 |
| tox21_202554 |
| NCGC00257989-01 |
| cas-25167-70-8 |
| dsstox_cid_6765 |
| dtxsid4026765 , |
| FT-0624979 |
| FT-0624980 |
| AKOS015903731 |
| 2,4,4-trimethyl-1-pentene [hsdb] |
| (tert-c4h9)ch2c(ch3)=ch2 |
| 2,4,4-trimethyl-pentene-1 |
| tmp-1 |
| 2,4,4-trimethylpentene-1 |
| 2,4,4 trimethyl-1-pentene |
| W-109188 |
| CHEMBL3186786 |
| isooctene(7ci,8ci,9ci) |
| J-001894 |
| mfcd00008855 |
| diisobutylene, technical, >=90% (3 parts 2,4,4-trimethyl-1-pentene + 1 part 2,4,4-trimethyl-2-pentene, gc) |
| 1-pentene, 2,4,4-trimethyl-; 2,4,4-trimethyl-1-pentene; 1-methyl-1-neopentylethylene; 2,2,4-trimethyl-4-pentene; nsc 73942; nsc 8701 |
| Q3030100 |
| D92377 |
| a-diisobutylene |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Together with the distribution for the benchmark dose obtained from substance-specific dose-response modelling for the exemplary substances 2,4,4-trimethylpentene (TMP) and aniline, they represent the input distributions for probabilistic modelling." | ( A probabilistic effect assessment model for hazardous substances at the workplace. Darschnik, S; Elmshäuser, E; Hassauer, M; Mosbach-Schulz, O; Schneider, K; Schuhmacher-Wolz, U, 2006) | 0.33 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| acetylcholinesterase | Homo sapiens (human) | Potency | 70.9220 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 6.8520 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 10 (58.82) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (40.60) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||